PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials
Background: Small Cell Lung Cancer (SCLC) is a neuroendocrine carcinoma characterized by aggressive behavior and poor prognosis with limited treatment options. Poly ADP-Ribose Polymerase inhibitors (PARPi) are novel anti-cancer agents that induce DNA damages and cause cell death in tumor cells with...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | Cancer Treatment and Research Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294225000127 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|